An Exploratory Study of the Effect of Treatment Interruption on Safety of Exenatide in Patients with Type 2 Diabetes

Study identifier:H8O-MC-GWBO

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

An Exploratory Study of the Effect of Treatment Interruption on Safety of Exenatide in Patients with Type 2 Diabetes

Medical condition

Type 2 Diabetes Mellitus

Phase

Phase 3

Healthy volunteers

No

Study drug

exenatide

Sex

All

Actual Enrollment

58

Study type

Interventional

Age

20 Years +

Date

Study Start Date: 01 Aug 2007
Primary Completion Date: 01 Apr 2008
Study Completion Date: 01 Apr 2008

Study design

Allocation: Non-randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Mar 2015 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

Eli Lilly and Company

Inclusion and exclusion criteria